Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly presents Gemzar study data

Lilly presents Gemzar study data

1st June 2009

Lilly presented data from its phase III clinical trial of Gemzar (gemcitabine HCl for injection) at the 45th Annual Meeting of the American Society of Clinical Oncology yesterday (May 31st).

The investigation examined the use of the drug along with the current standard of care in patients with locally advanced cervical cancer ? which, since 1999, has been chemotherapy cisplatin and radiation (chemoradiation).

Data from the study suggested it could significantly increase the survival rate of women at a three-year point.

Lead author Dr Alfonso Duenas-Gonzalez noted even though there have been “tremendous advances in cervical cancer prevention” over recent years, the same treatment has essentially been used for the last decade.

Vice-president of Lilly’s cancer research division Dr Richard Gaynor also commented on the topic.

“[We] continue to look for ways to improve the survival of people living with cancer and fill unmet needs in difficult to treat cancers,” he said.

Last week, the Committee for Medicinal Products for Human Use issued a positive opinion of Almita (pemetrexed for injection).

The drug has been developed by Lilly as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.